Northland Securities reissued their sell rating on shares of DexCom (NASDAQ:DXCM) in a report issued on Tuesday. They currently have a $40.00 price objective on the medical device company’s stock.

Several other equities analysts have also commented on DXCM. Piper Jaffray Companies reissued a buy rating and set a $87.00 price objective on shares of DexCom in a research report on Thursday, September 28th. Barclays reissued a hold rating and set a $60.00 price objective on shares of DexCom in a research report on Monday, January 8th. Leerink Swann reissued a buy rating and set a $57.00 price objective (down previously from $85.00) on shares of DexCom in a research report on Friday, September 29th. Oppenheimer lowered their price objective on DexCom from $92.00 to $85.00 and set an outperform rating for the company in a research report on Thursday, September 28th. Finally, Cowen lowered their price objective on DexCom from $90.00 to $64.00 and set an outperform rating for the company in a research report on Thursday, September 28th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and fourteen have given a buy rating to the stock. The company has an average rating of Buy and a consensus target price of $68.50.

DexCom (DXCM) traded down $0.23 during trading hours on Tuesday, reaching $56.05. 1,157,253 shares of the company traded hands, compared to its average volume of 1,978,369. The company has a market capitalization of $4,870.00, a PE ratio of -98.33 and a beta of 0.31. DexCom has a twelve month low of $42.62 and a twelve month high of $86.32. The company has a current ratio of 5.86, a quick ratio of 5.50 and a debt-to-equity ratio of 0.84.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Wednesday, November 1st. The medical device company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.11. DexCom had a negative net margin of 7.21% and a negative return on equity of 20.44%. analysts predict that DexCom will post -0.65 earnings per share for the current fiscal year.

In other DexCom news, EVP Andrew K. Balo sold 6,490 shares of the business’s stock in a transaction dated Wednesday, November 29th. The stock was sold at an average price of $60.00, for a total value of $389,400.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Terrance H. Gregg sold 10,000 shares of the business’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $56.86, for a total value of $568,600.00. Following the completion of the transaction, the insider now directly owns 484,559 shares of the company’s stock, valued at approximately $27,552,024.74. The disclosure for this sale can be found here. In the last ninety days, insiders sold 48,140 shares of company stock valued at $2,727,176. 1.70% of the stock is owned by insiders.

A number of large investors have recently modified their holdings of the business. FMR LLC raised its position in DexCom by 9.9% in the 2nd quarter. FMR LLC now owns 10,824,306 shares of the medical device company’s stock worth $791,799,000 after buying an additional 978,898 shares during the last quarter. Janus Henderson Group PLC raised its position in DexCom by 29.2% in the 3rd quarter. Janus Henderson Group PLC now owns 8,819,825 shares of the medical device company’s stock worth $431,510,000 after buying an additional 1,991,094 shares during the last quarter. Vanguard Group Inc. raised its position in DexCom by 3.4% in the 2nd quarter. Vanguard Group Inc. now owns 6,821,102 shares of the medical device company’s stock worth $498,963,000 after buying an additional 224,808 shares during the last quarter. BlackRock Inc. raised its position in DexCom by 5.5% in the 2nd quarter. BlackRock Inc. now owns 4,391,404 shares of the medical device company’s stock worth $321,232,000 after buying an additional 230,542 shares during the last quarter. Finally, Brown Advisory Inc. raised its position in DexCom by 57.2% in the 3rd quarter. Brown Advisory Inc. now owns 4,165,522 shares of the medical device company’s stock worth $203,798,000 after buying an additional 1,515,134 shares during the last quarter.

TRADEMARK VIOLATION WARNING: This news story was reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.watchlistnews.com/northland-securities-reaffirms-sell-rating-for-dexcom-dxcm/1814296.html.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.